TY - JOUR
T1 - Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia
AU - Savage, Sharon A.
AU - Viard, Mathias
AU - O'hUigin, Colm
AU - Zhou, Weiyin
AU - Yeager, Meredith
AU - Li, Shengchao Alfred
AU - Wang, Tao
AU - Ramsuran, Veron
AU - Vince, Nicolas
AU - Vogt, Aurelie
AU - Hicks, Belynda
AU - Burdett, Laurie
AU - Chung, Charles
AU - Dean, Michael
AU - de Andrade, Kelvin C.
AU - Freedman, Neal D.
AU - Berndt, Sonja I.
AU - Rothman, Nathaniel
AU - Lan, Qing
AU - Cerhan, James R.
AU - Slager, Susan L.
AU - Zhang, Yawei
AU - Teras, Lauren R.
AU - Haagenson, Michael
AU - Chanock, Stephen J.
AU - Spellman, Stephen R.
AU - Wang, Youjin
AU - Willis, Amanda
AU - Askar, Medhat
AU - Lee, Stephanie J.
AU - Carrington, Mary
AU - Gadalla, Shahinaz M.
N1 - Funding Information:
This work was supported by the intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI). The Center for International Blood and Marrow Transplant Research (CIBMTR) is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the NCI, the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant/Cooperative Agreement 4U10HL069294 from the NHLBI and the NCI; contract HHSH250201200018C with the Health Resources and Services Administration (HRSA/DHHS); and two grants, N00014-17-1-2388 and N0014-17-1-2850, from the Office of Naval Research. The Mayo Clinic Case-Control Study of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (MAYO) study is funded through grants R01 CA92153 and P50 CA97274. The NCI Surveillance, Epidemiology, and End Results Non-Hodgkin Lymphoma Case-Control Study (NCI-SEER) study is funded by the Intramural Research Program of the NCI, National Institutes of Health (NIH), and Public Health Service (N01-PC-65064, N01-PC-67008, N01-PC-67009, N01-PC-67010, and N02-PC-71105). The Population-based Case-Control Study in Connecticut Women (YALE) is funded through the NCI (CA62006 and CA165923). This project has also been funded in part with federal funds from the Frederick National Laboratory for Cancer Research, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported in part by the Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research. V.R. is supported by the African Academy of Sciences (AAS) and the Royal Society, which is funded by the UK Government as part of the Global Challenge Research Fund (GCRF); and V.R. is also supported by the South African Medical Research Council (SAMRC) with funds from the Department of Science and Technology (DST). V.R. is funded in part through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a Developing Excellence in Leadership Training and Science (DELTAS) Africa Initiative (grant # DEL-15-006) by the AAS.
Funding Information:
This work was supported by the intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute ( NCI ). The Center for International Blood and Marrow Transplant Research ( CIBMTR ) is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the NCI , the National Heart, Lung and Blood Institute ( NHLBI ), and the National Institute of Allergy and Infectious Diseases ( NIAID ); Grant/Cooperative Agreement 4U10HL069294 from the NHLBI and the NCI ; contract HHSH250201200018C with the Health Resources and Services Administration ( HRSA/DHHS ); and two grants, N00014-17-1-2388 and N0014-17-1-2850 , from the Office of Naval Research . The Mayo Clinic Case-Control Study of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (MAYO) study is funded through grants R01 CA92153 and P50 CA97274 . The NCI Surveillance, Epidemiology, and End Results Non-Hodgkin Lymphoma Case-Control Study (NCI-SEER) study is funded by the Intramural Research Program of the NCI, National Institutes of Health (NIH), and Public Health Service ( N01-PC-65064 , N01-PC-67008 , N01-PC-67009 , N01-PC-67010 , and N02-PC-71105 ). The Population-based Case-Control Study in Connecticut Women (YALE) is funded through the NCI ( CA62006 and CA165923 ). This project has also been funded in part with federal funds from the Frederick National Laboratory for Cancer Research , under Contract No. HHSN261200800001E . The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported in part by the Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research . V.R. is supported by the African Academy of Sciences (AAS) and the Royal Society, which is funded by the UK Government as part of the Global Challenge Research Fund (GCRF); and V.R. is also supported by the South African Medical Research Council (SAMRC) with funds from the Department of Science and Technology (DST). V.R. is funded in part through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a Developing Excellence in Leadership Training and Science (DELTAS) Africa Initiative (grant # DEL-15-006 ) by the AAS.
Publisher Copyright:
© 2020
PY - 2020/2/6
Y1 - 2020/2/6
N2 - Severe aplastic anemia (SAA) is a rare disorder characterized by hypoplastic bone marrow and progressive pancytopenia. The etiology of acquired SAA is not understood but is likely related to abnormal immune responses and environmental exposures. We conducted a genome-wide association study of individuals with SAA genetically matched to healthy controls in discovery (359 cases, 1,396 controls) and validation sets (175 cases, 1,059 controls). Combined analyses identified linked SNPs in distinct blocks within the major histocompatibility complex on 6p21. The top SNP encodes p.Met76Val in the P4 binding pocket of the HLA class II gene HLA-DPB1 (rs1042151A>G, odds ratio [OR] 1.75, 95% confidence interval [CI] 1.50–2.03, p = 1.94 × 10−13) and was associated with HLA-DP cell surface expression in healthy individuals (p = 2.04 × 10−6). Phylogenetic analyses indicate that Val76 is not monophyletic and likely occurs in conjunction with different HLA-DP binding groove conformations. Imputation of HLA-DPB1 alleles revealed increased risk of SAA associated with Val76-encoding alleles DPB1∗03:01, (OR 1.66, p = 1.52 × 10−7), DPB1∗10:01 (OR 2.12, p = 0.0003), and DPB1∗01:01 (OR 1.60, p = 0.0008). A second SNP near HLA-B, rs28367832G>A, reached genome-wide significance (OR 1.49, 95% CI 1.22–1.78, p = 7.27 × 10−9) in combined analyses; the association remained significant after excluding cases with clonal copy-neutral loss-of-heterozygosity affecting class I HLA genes (8.6% of cases and 0% of controls). SNPs in the HLA class II gene HLA-DPB1 and possibly class I (HLA-B) are associated with SAA. The replacement of Met76 to Val76 in certain HLA-DPB1 alleles might influence risk of SAA through mechanisms involving DP peptide binding specificity, expression, and/or other factors affecting DP function.
AB - Severe aplastic anemia (SAA) is a rare disorder characterized by hypoplastic bone marrow and progressive pancytopenia. The etiology of acquired SAA is not understood but is likely related to abnormal immune responses and environmental exposures. We conducted a genome-wide association study of individuals with SAA genetically matched to healthy controls in discovery (359 cases, 1,396 controls) and validation sets (175 cases, 1,059 controls). Combined analyses identified linked SNPs in distinct blocks within the major histocompatibility complex on 6p21. The top SNP encodes p.Met76Val in the P4 binding pocket of the HLA class II gene HLA-DPB1 (rs1042151A>G, odds ratio [OR] 1.75, 95% confidence interval [CI] 1.50–2.03, p = 1.94 × 10−13) and was associated with HLA-DP cell surface expression in healthy individuals (p = 2.04 × 10−6). Phylogenetic analyses indicate that Val76 is not monophyletic and likely occurs in conjunction with different HLA-DP binding groove conformations. Imputation of HLA-DPB1 alleles revealed increased risk of SAA associated with Val76-encoding alleles DPB1∗03:01, (OR 1.66, p = 1.52 × 10−7), DPB1∗10:01 (OR 2.12, p = 0.0003), and DPB1∗01:01 (OR 1.60, p = 0.0008). A second SNP near HLA-B, rs28367832G>A, reached genome-wide significance (OR 1.49, 95% CI 1.22–1.78, p = 7.27 × 10−9) in combined analyses; the association remained significant after excluding cases with clonal copy-neutral loss-of-heterozygosity affecting class I HLA genes (8.6% of cases and 0% of controls). SNPs in the HLA class II gene HLA-DPB1 and possibly class I (HLA-B) are associated with SAA. The replacement of Met76 to Val76 in certain HLA-DPB1 alleles might influence risk of SAA through mechanisms involving DP peptide binding specificity, expression, and/or other factors affecting DP function.
KW - GWAS
KW - HLA
KW - HLA-DP
KW - aplastic anemia
KW - bone marrow failure
KW - etiology
KW - genome-wide association study
KW - hematpoietic cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=85078796083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078796083&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2020.01.004
DO - 10.1016/j.ajhg.2020.01.004
M3 - Article
C2 - 32004448
AN - SCOPUS:85078796083
SN - 0002-9297
VL - 106
SP - 264
EP - 271
JO - American journal of human genetics
JF - American journal of human genetics
IS - 2
ER -